|
|
 |
|
Viewing report
|
|
|
|
Lead Optimization Strategies: Future Developments, Threats and Opportunities For Big Pharma, Specialty Pharma and Biotech
Business Insights, Sep 2005
The pharmaceutical industry has undergone considerable consolidation during the last 20 years as companies attempt to maintain double-digit sales growth and shareholder value. Strategic mergers and acquisitions have resulted in companies revitalizing their drug pipelines to replace blockbuster drugs that face patent expiration.
In many cases, whilst mergers cause a period of less productive transition, significant cost-savings can be reaped and overheads reduced. However, more and more companies are resorting to streamlining their internal programs, both pre-clinical and clinical, to improve productivity and the cost-effectiveness of bringing drugs to the market as well as in-licensing late-stage products and outsourcing screening programs which may be less economical to entertain in-house.
This report includes case studies of the following companies:
- AstraZeneca
- GlaxoSmithKline
- ArQule
- Locus Pharmaceuticals
Customers who bought this item also bought
Hit and Lead Profiling: Identification and Optimization of Drug-like Molecules
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Accelerating Lead Generation: Emerging Technologies and Strategies
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
A Guidebook to Pharma Brand Optimization: Lifecycle Management Strategy
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Translational Medicine in Biopharmaceutical R&D: Enabling R&D Optimization and Early Detection of Potential Failures
Organic and Medicinal Chemistry in Drug Discovery: Pharma's Intelligent Design
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
Surviving The Optimization Evolution (Strategy Focus)
High Throughput Screening
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
|
|
|
|
